NCT07499661

Brief Summary

This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it. Doctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot. However, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart failure who die may actually have had an undiagnosed pulmonary embolism. Current medical guidelines recommend checking for pulmonary embolism when the cause of breathing problems is unclear, but in real-life practice, this is not always done. The goal of this study is to find out whether pulmonary embolism is underdiagnosed in patients with suspected acute heart failure and whether systematically testing for it could improve patient outcomes. To do this, the study will compare two approaches in several hospitals. In half of the hospitals, doctors will follow their usual practice and decide case by case whether to test for pulmonary embolism. In the other half, doctors will systematically test all eligible patients for pulmonary embolism using recommended diagnostic methods. Adult patients admitted with recent or worsening breathing difficulties and signs of acute heart failure may be included in the study, provided they give their consent. Researchers will collect information about their symptoms, tests, diagnosis, and treatments. Patients will be monitored during their hospital stay and for three months afterward. The study will track important outcomes such as survival, new blood clots, bleeding events, repeated hospital visits for breathing problems, and overall time spent in the hospital. The researchers expect to include about 740 patients in total. They estimate that pulmonary embolism may be found in about 1% of patients with usual care, but up to 5% when doctors systematically look for it. This study aims to better understand how often pulmonary embolism occurs in patients with acute heart failure and whether more systematic testing could lead to earlier diagnosis and better care. The results could help improve medical practice and reduce complications or deaths related to missed diagnoses.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
740

participants targeted

Target at P75+ for not_applicable

Timeline
27mo left

Started Jun 2026

Typical duration for not_applicable

Geographic Reach
1 country

10 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Jun 2026Sep 2028

First Submitted

Initial submission to the registry

March 24, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 30, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2028

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

2 years

First QC Date

March 24, 2026

Last Update Submit

March 24, 2026

Conditions

Keywords

Cluster-randomized trial

Outcome Measures

Primary Outcomes (1)

  • Rate of pulmonary embolism

    Rate of pulmonary embolism (PE) diagnosed within 48 hours after hospital admission. PE must be objectively confirmed and the diagnosis validated by an independent adjudication committee blinded to study group allocation.

    48 hours

Study Arms (2)

Interventional arm

EXPERIMENTAL
Diagnostic Test: Systematic screening for pulmonary embolism in all patients using a guideline-recommended diagnostic algorithm

Observational arm

NO INTERVENTION

Interventions

In intervention centers, physicians will systematically screen all patients for pulmonary embolism (PE) using guideline-recommended algorithms. The revised Geneva score will be assessed for each patient. If clinical probability is low or moderate (≤10), highly sensitive D-dimer testing will be performed. PE will be excluded if D-dimer levels are below 500 µg/L (under 50 years) or below the age-adjusted threshold (age × 10 µg/L for patients ≥50 years). For patients with elevated D-dimers or high clinical probability, a 4-point compression venous ultrasound will be performed. If positive, PE will be confirmed. If negative or inconclusive, CT pulmonary angiography will be conducted. All diagnostic procedures must be completed within 48 hours of admission.

Interventional arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient (≥18 years)
  • Admission to the emergency department or cardiology unit of a participating center
  • Recent onset or worsening dyspnea and/or orthopnea
  • Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following:
  • Bilateral pulmonary crackles on auscultation and/or peripheral edema
  • Signs of pulmonary congestion on chest X-ray or lung/cardiac ultrasound
  • Elevated natriuretic peptide levels (BNP or NT-proBNP)
  • Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure)
  • Patient affiliated with or beneficiary of a social security system
  • Patient able and willing to provide free, informed, and written consent

You may not qualify if:

  • Shock state suggesting cardiogenic shock and/or severe pulmonary embolism
  • Evidence of acute coronary syndrome on electrocardiogram at admission
  • Severe renal impairment (creatinine clearance \<30 mL/min)
  • Known hypersensitivity or allergy to iodinated contrast agents
  • Ongoing therapeutic anticoagulation for more than 48 hours prior to admission
  • Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable)
  • Inadequate understanding of the French language preventing proper study information and consent
  • Pregnant, breastfeeding, or postpartum women
  • Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Agen Hospital, Emergency department

Agen, 47923, France

Location

Angers University Hospital, Emergency Department

Angers, 49000, France

Location

Brest University Hospital (site Cavale Blanche), Cardiology Department

Brest, 29200, France

Location

Tours University Hospital (site Trousseau), Adult Emergency Department

Chambray-lès-Tours, 37170, France

Location

Cholet Hospital, Emergency Department

Cholet, 49300, France

Location

Clermont-Ferrand University Hospital, Emergency Department

Clermont-Ferrand, 63000, France

Location

Grenoble Alpes University Hospital, Adult Emergency Department

La Tronche, 38700, France

Location

Lyon University Hospital (site Edouard Herriot), Emergency Department

Lyon, 69003, France

Location

Poitiers University Hospital, Emergency Department

Poitiers, 86000, France

Location

Toulouse University Hospital, Emergency Department

Toulouse, 31000, France

Location

MeSH Terms

Conditions

Pulmonary EmbolismDiseaseVenous Thromboembolism

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsThromboembolism

Study Officials

  • Delphine Douillet, Professor

    University Hospital of Angers, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2026

First Posted

March 30, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

September 1, 2028

Last Updated

March 30, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations